ClinicalTrials.gg

Program

AK138D1

A development code.

Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Breast Neoplasms, led by Akeso.

Furthest: phase 2, since Apr 24, 20264 company-led studies, 4 open or runningNext primary completion: Feb 26, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Akeso44 open or runningphase 2since Apr 24, 2026Dec 9, 2024Feb 26, 2028phase 1 · NCT06730386

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 9, 2024First study: phase 1 study in Solid CancerFirst studyNCT06730386 · 100 planned · Australia
  2. Sep 25, 2025Phase 1 study in Solid CancerNCT07281326 · 200 planned · China
  3. Apr 24, 2026Phase 2 study in Breast NeoplasmsPhase 2 reachedNCT07560124 · 286 planned · China
  4. May 28, 2026Phase 2 study in Carcinoma, Non-Small-Cell LungNCT07623356 · 265 planned · China

Ahead

  1. Feb 26, 2028Primary completion: phase 1 study in Solid CancerNCT06730386
  2. Jun 6, 2028Primary completion: phase 2 study in Breast NeoplasmsNCT07560124
  3. Jun 18, 2028Primary completion: phase 2 study in Carcinoma, Non-Small-Cell LungNCT07623356

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07623356Carcinoma, Non-Small-Cell Lung · China2RecruitingJun 18, 2028265
NCT07560124Breast Neoplasms · China2Not yet recruitingJun 6, 2028286
NCT07281326Solid Cancer · China1RecruitingOct 22, 2026200
NCT06730386Solid Cancer · Australia1RecruitingFeb 26, 2028100

How it is read

Names in the registry

  • “AK138D1”, 4 entries

Codes read as this program: AK138D1.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.